Flu Shot Candidate Proceeds With More Universal Immune Response

Osivax, a biopharmaceutical company, today announced that all participants have completed their final visit in the Phase 2a clinical trial (NCT05734040) evaluating OVX836, a broad-spectrum influenza A vaccine candidate, in combination with Quadrivalent Influenza Vaccines (QIVs).

Topline results from this study are expected in the second half of 2024. OVX836 has been tested in 5 clinical trials with 1,200 participants, showing promising safety, immunogenicity, and efficacy read-outs. 

OVX836 is a first-in-class influenza A vaccine candidate that targets the nucleoprotein (NP), a highly conserved internal antigen.

Unlike surface antigens, the NP is much less likely to mutate, providing a broader and more universal immune response.

Osivax’s oligoDOMTM technology enables the design and production of a recombinant version of the NP, which self-assembles into a nanoparticle and thus triggers powerful T- and B-cell immune responses.

“The need for more effective and safe flu vaccines remains high, and the conclusion of our trial, which evaluates OVX836 in combination with QIVs, brings us one step closer to providing improved protection,” said Alexandre Le Vert, CEO and Co-Founder of Osivax, in a press release on March 26, 2024.

According to various reports, most flu shots offered about 50% protection during the 2023-2024 influenza season in the U.S.